SCHEMBL25254029

SCHEMBL25254029

COc1ccc(OC)c(-c2cnc3cc(C(=O)O)ccn23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
HPGD P15428 2/20 0.44
TSHR P16473 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
ADRA2B P18089 1/20 0.43
STIM1 Q13586 1/20 0.43
ORAI1 Q96D31 1/20 0.43
FLT3 P36888 2/20 0.43
KDM4E B2RXH2 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25252394 0.90 ADRA2B (0.45) MAPTADRA2BFLT3CA1CA2
SCHEMBL22588077 0.88 FLT3 (0.46) LMNAHPGDTSHRNPSR1ALDH1A1
SCHEMBL22588291 0.87 ADRA2B (0.45) LMNATSHRADRA2BFLT3CA12
SCHEMBL22588450 0.86 ADRA2B (0.55) ADRA2BRIPK2MRGPRX4
SCHEMBL22588302 0.84 FLT3 (0.44) LMNAADRA2BFLT3KDM4CMAPK1
SCHEMBL23675330 0.83 FLT3 (0.62) ALDH1A1FLT3KDM4ECA1CA2
SCHEMBL22588098 0.78 FLT3 (0.45) HPGDTSHRNPSR1ALDH1A1MAPT
SCHEMBL22366411 0.77 ADRA2B (0.56) HPGDADRA2B
SCHEMBL22588776 0.75 ADRA2B (0.57) ADRA2BRIPK2
SCHEMBL22588425 0.75 HPGD (0.42) HPGDADRA2BFLT3CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
EP-4192459-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2023-06-14 EP disclosed
CN-116234549-A Salt-induced kinase inhibitors 总医院公司 2023-06-06 CN disclosed
WO-2022031928-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 LMNA 2900/4885HPGD 3692/4885TSHR 1374/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 LMNA 3886/4885HPGD 2931/4885TSHR 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.